loading...| Preferred Name | leflunomide | |
| Synonyms |
SU101 Arava 4-isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)- |
|
| Definitions |
A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties. As a prodrug, leflunomide is converted to an active metabolite, A77 1726, which blocks dihydroorotate dehydrogenase, a key enzyme of de novo pyrimidine synthesis, thereby preventing the expansion of activated T lymphocytes. This agent also inhibits various protein tyrosine kinases, such as protein kinase C (PKC), thereby inhibiting cell proliferation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1128" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1128" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000042253 |
|
| altLabel |
SU101 Arava 4-isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)- |
|
| CAS Registry |
75706-12-6 |
|
| Component of | ||
| cui |
C0063041 C0966994 C0718644 |
|
| Date last modified |
2006-12-21 |
|
| definition |
A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties. As a prodrug, leflunomide is converted to an active metabolite, A77 1726, which blocks dihydroorotate dehydrogenase, a key enzyme of de novo pyrimidine synthesis, thereby preventing the expansion of activated T lymphocytes. This agent also inhibits various protein tyrosine kinases, such as protein kinase C (PKC), thereby inhibiting cell proliferation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1128" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1128" NCI Thesaurus) |
|
| Legacy PDQ ID |
5501 |
|
| LT |
TRD |
|
| NCI ID |
C1128 |
|
| notation |
CDR0000042253 |
|
| NSC Code |
677411 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
leflunomide |
|
| tui |
T109 T121 |